AIM OF THE STUDY: mRNA expression of genes involved in the mechanism of action of pemetrexed was correlated with in vitro chemosensitivity of freshly explanted human tumor specimens. EXPERIMENTAL DESIGN: Chemosensitivity to pemetrexed was studied in soft-agar. Multiplex rtPCR experiments for reduced folate carrier (RFC), folate receptor-alpha (FR-alpha), folylpolyglutamate synthetase (FPGS), thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyl transferase (GARFT), mrp4, and mrp5 were performed in parallel. Correlations, threshold optimization, sensitivity, specificity, and efficiency were analyzed using the appropriate statistical methodologies. RESULTS: In 61 samples, low levels of TS, GARFT, DHFR, and mrp4 gene expression significantly correlated with chemosensitivity to pemetrexed. Optimization analyses demonstrated threshold values of 144 copies for TS and six copies for mrp4 relative to 10(4) copies of beta-actin. CONCLUSIONS: These results form a rational basis for the design of clinical trials to evaluate the expression of these enzymes as predictors for treatment outcome.
AIM OF THE STUDY: mRNA expression of genes involved in the mechanism of action of pemetrexed was correlated with in vitro chemosensitivity of freshly explanted humantumor specimens. EXPERIMENTAL DESIGN: Chemosensitivity to pemetrexed was studied in soft-agar. Multiplex rtPCR experiments for reduced folate carrier (RFC), folate receptor-alpha (FR-alpha), folylpolyglutamate synthetase (FPGS), thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyl transferase (GARFT), mrp4, and mrp5 were performed in parallel. Correlations, threshold optimization, sensitivity, specificity, and efficiency were analyzed using the appropriate statistical methodologies. RESULTS: In 61 samples, low levels of TS, GARFT, DHFR, and mrp4 gene expression significantly correlated with chemosensitivity to pemetrexed. Optimization analyses demonstrated threshold values of 144 copies for TS and six copies for mrp4 relative to 10(4) copies of beta-actin. CONCLUSIONS: These results form a rational basis for the design of clinical trials to evaluate the expression of these enzymes as predictors for treatment outcome.
Authors: D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg Journal: Clin Cancer Res Date: 2000-04 Impact factor: 12.531
Authors: H J Lenz; C G Leichman; K D Danenberg; P V Danenberg; S Groshen; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; Y Garcia; J Li; L Leichman Journal: J Clin Oncol Date: 1996-01 Impact factor: 44.544
Authors: Henry L Gomez; Sergio L Santillana; Carlos S Vallejos; Raul Velarde; Juvenal Sanchez; Xinpeng Wang; Nancy L Bauer; Richard D Hockett; Victor J Chen; Clet Niyikiza; Axel R Hanauske Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531
Authors: G R Westerhof; J H Schornagel; I Kathmann; A L Jackman; A Rosowsky; R A Forsch; J B Hynes; F T Boyle; G J Peters; H M Pinedo Journal: Mol Pharmacol Date: 1995-09 Impact factor: 4.436
Authors: Jennifer Sigmond; Harold H J Backus; Dorine Wouters; Olaf H Temmink; Gerrit Jansen; Godefridus J Peters Journal: Biochem Pharmacol Date: 2003-08-01 Impact factor: 5.858
Authors: A Paradiso; G Simone; S Petroni; B Leone; C Vallejo; J Lacava; A Romero; M Machiavelli; M De Lena; C J Allegra; P G Johnston Journal: Br J Cancer Date: 2000-02 Impact factor: 7.640
Authors: Boyka Markova; Patricia S Hähnel; Stefan Kasper; Stephan Herbertz; Martin Schuler; Frank Breitenbuecher Journal: J Cancer Res Clin Oncol Date: 2011-12-28 Impact factor: 4.553
Authors: Cheng E Chee; James R Jett; Albert M Bernath; Nathan R Foster; Garth D Nelson; Julian Molina; Daniel A Nikcevich; Preston D Steen; Patrick J Flynn; Kendrith M Rowland Journal: Cancer Date: 2010-05-15 Impact factor: 6.860